Swiss National Science Foundation Funds Swiss & Norwegian Investigators Targeting Pediatric Brain Tumors for Novel Medicines

Swiss National Science Foundation Funds Swiss & Norwegian Investigators Targeting Pediatric Brain Tumors for Novel Medicines

A consortium involving principal investigators in Switzerland and Norway were awarded a CHF 3.1 million (USD $3.5m) grant from Swiss National Science Foundation (SNSF) to identify novel treatment approaches for children with deadly brain tumors. With the funds, the “Sinergia consortium” includes principal investigators from the DMG/DIPG Center Zurich at University Children’s Hospital, the ETH Zurich and the Centre for Molecular Medicine Norway (NCMM). The group seeks to develop novel approaches involving precision medicine in pediatric diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG).

The Challenge

An aggressive and deadly brain tumor, DMG/DIPG primarily affects children but can also impact adults. Survival time for patients is not good, with over 90% of DMG/DIPG patients passing away within two years of diagnosis. Although some progress has been made involving an understanding of the molecular biology associated with these tumors, when it comes to novel and effective drugs—or combinations—little progress has been made

The Study

The funding was awarded to help the Sinergia consortium discover therapeutic vulnerabilities in patient-derived precli...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee